Rheumatology

1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the...

1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus...

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic...

1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to...

1. Reduced-dose glucocorticoid plus rituximab regimen was non-inferior compared to high-dose glucocorticoid plus rituximab regimen for induction of disease remission...

1. Among a large, matched cohort of veterans with rheumatoid arthritis, initiation of hydroxychloroquine was not associated with a higher...

1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib...

1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab...